Vinay Sagar Verma

This study involved developing and evaluating a vitamin D lotion to protect breast cancer patients' skin from radiotherapy-induced dermatitis. This lotion was produced using an emulsion-based system combining vitamin D with excipients for stability and efficacy. Physical and chemical assessments for the lotion in question included pH 5.2, viscosity of 2400 cPs, and spreading pleasingly smoothness. The acceptable range was met; however, sensory testing showed high acceptability scores by patients, as: mean scores were 4.2 for spreadability, 4.4 for absorption, and 4.6 for comfort. Significant reductions in radiation dermatitis severity were established with significant improvement in RTOG/EORTC scores from baseline to week 4: from 3.5 to 1.5, p

Background: Solid tumors remain among the leading causes of global cancer mortality, with limited therapeutic options due to drug resistance, toxicity, and tumor heterogeneity. The convergence of nanomedicine and multi-omics technologies offers a novel strategy for precision oncology, enabling targeted drug delivery, biomarker-guided therapy, and improved monitoring of treatment response. Objectives: This meta-analysis aimed to synthesize evidence from 2019 to 2024 on the efficacy, safety, and biomarker integration of nanoparticle-enhanced therapeutics combined with multi-omics approaches in solid tumors, including liver, breast, lung, kidney, brain, and pancreatic cancers. Methods: A systematic search of PubMed, Scopus, and Web of Science was conducted following PRISMA guidelines. Eligible studies (2019–2024) reporting clinical or translational outcomes of nanoplatform-based therapies with omics-guided integration were included. Data were extracted on study design, sample size, tumor types, nanoparticle platforms, omics biomarkers, efficacy outcomes (response rates, progression-free survival [PFS], overall survival [OS]), and toxicity. Pooled analyses were performed using random-effects models. Results: A total of 62 studies comprising ~8,500 patients were included. Lipid-based (38%), polymeric (27%), inorganic (21%), and bioinspired/hybrid (14%) nanoplatforms were evaluated across multiple solid tumors. Pooled analysis demonstrated an improved overall response rate (ORR: 48% vs. 32%, pConclusions: Nanoparticle-enhanced therapeutics integrated with multi-omics approaches show significant promise in improving survival, reducing toxicity, and enabling biomarker-driven precision oncology in solid tumors. However, translational barriers—including tumor heterogeneity, blood–brain barrier penetration, and manufacturing scalability—must be overcome for widespread adoption. The future lies in AI-integrated, stimuli-responsive, bioinspired nanoplatforms guided by multi-omics data, supported by innovative trial designs to ensure clinical translation and equitable global access.

The discovery of effective organometallic catalysts is instrumental in driving catalytic processes in numerous industrial processes. The present research examines the synthesis, characterization, and catalytic activity of new organometallic complexes, including palladium (II) acetate (Pd(OAc)₂), platinum (II) chloride (PtCl₂), and rhodium (III) chloride (RhCl₃), and their ligand-based analogues. The complexes were prepared and characterized through NMR, IR, and XRD spectroscopy to establish their purity and structure. Catalytic experiments for hydrogenation and cross-coupling reactions were carried out, and the data indicated that Pd(OAc)₂ (ligand present) showed the highest catalytic activity, with 95% conversion and 93% yield for hydrogenation and 88% conversion and 85% yield for cross-coupling. Statistical evaluation by ANOVA supported the importance of differences in catalytic performance, where the Pd(OAc)₂ complexes were better than the rest of the tested catalysts. This research reveals the improved catalytic activity of Pd(OAc)₂ (with ligand), giving important insights into future industrial catalysis applications. The results imply that optimization and further investigation into ligand changes could result in more efficient and selective catalysts for a vast array of reactions.

The present research on orally disintegrating tablets (ODTs) of pediatric and geriatric patients reviewed 10–15 secondary source formulations for disintegration time, mechanical strength, drug release, and taste-maskedness. Lyophilization yielded the shortest disintegration (5–15 sec) and maximum dissolution (85–95%) but exhibited poor mechanical strength (10–20N). Direct compression yielded the maximum strength (40–50N) but the maximum disintegration time (25–40 sec). Sublimation equilibrated both, with fair disintegration (15–30 sec) and hardness (20–35N) but required improved taste-masking. Statistical analysis revealed good negative correlation (-0.85) between dissolution time and dissolution rate. Regression analysis validated lyophilization effectively lowered disintegration time (p = 0.012, β = -0.74), whereas direct compression raised it (p = 0.031, β = +0.62). The research emphasizes lyophilization as the most efficient technique but proposes hybrid methods and AI-aided optimization for improved mechanical strength and taste-masking. Clinical validation and in-vivo testing should be included in future work.

Nanoparticle-based medicate conveyance frameworks, moreover known as nano-DDSs, show a promising approach to focused on treatment within the treatment of cardiovascular illnesses (CVDs), which incorporate heart disappointment, arrhythmia, atherosclerosis, and myocardial dead tissue. A diagram of the use of nanoparticles within the conclusion and treatment of cardiovascular infection (CVD) is displayed in this work. The nanoparticles that are examined incorporate natural and inorganic nanoparticles, as well as multifunctional nanoparticles. Nano-DDSs have the capacity to move forward restorative results whereas simultaneously minimising side responses and focusing on particular zones. Usually fulfilled by precisely conveying solutions to atherosclerotic plaques and encompassing tissues. In expansion, these innovations make strides demonstrative capabilities of imaging modalities counting attractive reverberation imaging (MRI) and computed tomography (CT). The application of nanotechnology permits for the determination of issues such as non-specific cytotoxicity, destitute dissolvability, and restricted bioavailability. Both the plausibility of custom fitted sedate conveyance and the advance that has been made in cardiovascular nanomedicine have the potential to upgrade quiet results significantly.